United Therapeutics Corporation increased its Board of Directors to 13 members following the appointment of Victor Dzau, M.D., effective July 22, 2026. Dr. Dzau, formerly President of the National Academy of Medicine, received 380 restricted stock units and 1,190 stock options as an initial grant, plus pro-rata grants of 350 restricted stock units and 1,110 stock options for the remainder of the 2026-2027 service year. The appointment is part of a board refreshment effort. United Therapeutics is a biotechnology company focused on developing treatments for rare diseases and organ alternatives.

At its 2026 Annual Meeting of Shareholders held on June 26, 2026, United Therapeutics Corporation shareholders approved the 2026 Stock Incentive Plan. This new plan, effective immediately, allows for the issuance of an aggregate number of common stock shares equal to the sum of 2,413,730 shares remaining from the prior 2015 plan plus 1,500,000 new shares, alongside shares from canceled or forfeited awards. Additionally, shareholders elected twelve directors, approved an advisory resolution regarding executive compensation, and ratified Ernst & Young LLP as the independent registered public accounting firm for 2026. United Therapeutics Corporation is a biotechnology company focused on developing therapies for serious diseases.